Giuseppe Salemi
Overview
Explore the profile of Giuseppe Salemi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1078
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schiro G, Iacono S, Andolina M, Sorbello G, Cali A, Gentile E, et al.
Ann Clin Transl Neurol
. 2025 Mar;
PMID: 40065529
Objective: People with multiple sclerosis (pwMS) may require a high level of daily assistance both for indoor and outdoor activities. Usually, relatives or friends provide daily support to MS patients...
2.
Frederiksen J, Massacesi L, Nielsen H, Rini A, Baldi E, Mirabella M, et al.
Mult Scler Relat Disord
. 2024 Dec;
93:106214.
PMID: 39642455
Background: Alemtuzumab is approved in the European Union for treating highly active relapsing-remitting multiple sclerosis (RRMS). Patient-reported outcomes measure the treatment impact on quality of life (QoL), including fatigue, a...
3.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 Sep;
271(10):7066-7068.
PMID: 39231861
No abstract available.
4.
Chisari C, Amato M, Di Sapio A, Foschi M, Iaffaldano P, Inglese M, et al.
J Neurol
. 2024 Aug;
271(10):6801-6810.
PMID: 39190108
'Active' and 'non-active' secondary progressive MS (SPMS) have distinct pathophysiological mechanisms and clinical characteristics, but there is still no consensus regarding the frequency of these MS forms in the real-world...
5.
Schiro G, Iacono S, Salemi G, Ragonese P
Expert Rev Neurother
. 2024 Aug;
24(10):985-996.
PMID: 39110029
Introduction: Myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD) is a clinical entity distinct from multiple sclerosis and aquaporin-4 (AQP4+)-IgG-positive neuromyelitis optica spectrum disorder. There is a lack of evidence regarding...
6.
Iacono S, Schiro G, Salemi G, Scire E, Aridon P, Melfa M, et al.
Neurol Int
. 2024 Jul;
16(4):761-775.
PMID: 39051217
Background: Therapeutic plasma exchange (TPE) is a highly effective rescue treatment for patients with acute exacerbation of neuroimmunological disease that removes circulating autoantibodies and inflammatory components from the bloodstream. The...
7.
Amato A, Proia P, Alioto A, Rossi C, Pagliaro A, Ragonese P, et al.
Sci Rep
. 2024 Jul;
14(1):16195.
PMID: 39003295
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease due to an autoimmune chronic inflammatory response, yet the etiology is currently not completely understood. It is already known that physical...
8.
Agnello L, Giglio R, Del Ben F, Piccoli T, Colletti T, Scazzone C, et al.
Sci Rep
. 2024 Jul;
14(1):16084.
PMID: 38992063
Cerebrospinal fluid (CSF) core biomarkers of Alzheimer's disease (AD), including amyloid peptide beta-42 (Aβ42), Aβ42/40 ratio, and phosphorylated tau (pTau), are precious tools for supporting AD diagnosis. However, their use...
9.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 May;
271(8):5074-5082.
PMID: 38805052
Objectives: We investigated the occurrence and relative contribution of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) to confirmed disability accrual (CDA) and transition to secondary progression (SP)...
10.
Chisari C, Aguglia U, Amato M, Bergamaschi R, Bertolotto A, Bonavita S, et al.
Neurotherapeutics
. 2024 May;
21(4):e00363.
PMID: 38714462
Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression...